Related references
Note: Only part of the references are listed.RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma
B. A. Wilky et al.
ONCOGENE (2016)
RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3
Min Xie et al.
CANCER RESEARCH (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells
Shuhei Ito et al.
PLOS ONE (2016)
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy
Guus M. Bol et al.
EMBO MOLECULAR MEDICINE (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer
Marise R. Heerma van Voss et al.
ONCOTARGET (2015)
DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway
H-H Chen et al.
ONCOGENE (2015)
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Peter Bouwman et al.
CLINICAL CANCER RESEARCH (2014)
Looking back on the birth of DEAD-box RNA helicases
Patrick Linder et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2013)
Expression of the RNA Helicase DDX3 and the Hypoxia Response in Breast Cancer
Guus M. Bol et al.
PLOS ONE (2013)
The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
Silvana B. De Lorenzo et al.
FRONTIERS IN ONCOLOGY (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein
Allan G. N. Angus et al.
JOURNAL OF GENERAL VIROLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
DNA resection in eukaryotes: deciding how to fix the break
Pablo Huertas
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Oncogenic role of DDX3 in breast cancer biogenesis
M. Botlagunta et al.
ONCOGENE (2008)
Quantifying synergism/antagonism using nonlinear mixed-effects modeling: A simulation study
John C. Boik et al.
STATISTICS IN MEDICINE (2008)
Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function
Yang Li et al.
CANCER RESEARCH (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
For and against - No consent should be needed for using leftover body material for scientific purposes - For
PJ van Diest
BMJ-BRITISH MEDICAL JOURNAL (2002)
The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
SR Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
